Anzalone Christopher Richard's Form 4 filing
Arrowhead Pharmaceuticals, Inc. (ARWR) · filed Apr 11, 2025
- Accession no.
- 0001628280-25-017592
- Filed
- Apr 11, 2025
- Trade date
- Apr 9-11, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.53M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Anzalone Christopher RichardCIK 0001423029 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 9, 2025 | Common Stock | SSaleDisposed | −35,305 | $9.93 | −$350,578.65 | 4,027,072 | Direct | |
| Apr 9, 2025 | Common Stock | SSaleDisposed | −3,400 | $10.75 | −$36,550 | 4,023,672 | Direct | |
| Apr 9, 2025 | Common Stock | SSaleDisposed | −1,617 | $11.76 | −$19,015.92 | 4,022,055 | Direct | |
| Apr 10, 2025 | Common Stock | SSaleDisposed | −50,000 | $10.87 | −$543,500 | 3,972,055 | Direct | |
| Apr 11, 2025 | Common Stock | SSaleDisposed | −50,800 | $11.49 | −$583,692 | 3,921,255 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.